AlphaQuest LLC Has $699,000 Stock Holdings in Tyra Biosciences, Inc. $TYRA

AlphaQuest LLC raised its holdings in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 146.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,073 shares of the company’s stock after purchasing an additional 43,451 shares during the quarter. AlphaQuest LLC owned approximately 0.14% of Tyra Biosciences worth $699,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Public Employees Retirement System of Ohio acquired a new stake in shares of Tyra Biosciences during the second quarter worth $177,000. Goldman Sachs Group Inc. increased its position in shares of Tyra Biosciences by 21.7% in the first quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company’s stock worth $725,000 after purchasing an additional 13,896 shares during the period. Rhumbline Advisers increased its position in shares of Tyra Biosciences by 7.2% in the first quarter. Rhumbline Advisers now owns 28,081 shares of the company’s stock worth $261,000 after purchasing an additional 1,879 shares during the period. Jane Street Group LLC bought a new position in shares of Tyra Biosciences in the first quarter worth $324,000. Finally, Woodline Partners LP bought a new position in shares of Tyra Biosciences in the first quarter worth $931,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Price Performance

Shares of NASDAQ:TYRA opened at $14.84 on Tuesday. The company has a market capitalization of $790.97 million, a PE ratio of -8.34 and a beta of 1.11. The business has a fifty day moving average price of $13.02 and a two-hundred day moving average price of $11.06. Tyra Biosciences, Inc. has a 1 year low of $6.42 and a 1 year high of $22.64.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.06. Sell-side analysts anticipate that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday, October 8th. Wall Street Zen upgraded Tyra Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, October 4th. Oppenheimer reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Tyra Biosciences in a research note on Wednesday, September 10th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Friday, August 22nd. Finally, Raymond James Financial started coverage on Tyra Biosciences in a research note on Tuesday, September 2nd. They issued a “strong-buy” rating and a $35.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Tyra Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.